Rx Pricing Practices Of US Trading Partners Criticized By Trade Office
Executive Summary
US Trade Representative also highlights restrictive patentability criteria in Canada, India and Indonesia in its annual Special 301 report.
You may also be interested in...
Pharma Patents Are Vulnerable In Canada As Lilly Loses NAFTA Challenge
Tribunal finds Lilly did not prove that Canada's promise utility doctrine discriminates against pharmaceutical patents; 25 pharma patents have been invalidated in past decade.
India Will Miss Investment Boat If New IPR Policy Just All Talk
India’s more muscular intellectual property protection policy is a good first step but the government will have to “walk the talk” to attract significant new investment from global pharmaceutical companies, say US experts. Implementation of the policy will be the key measure of its success, they say.
India's Patent Policy Needs More Stakeholder Input, US Trade Office Urges
'Watch List' from USTR also objects to China's definition of 'new drugs'; PhRMA criticizes practices in Canada and Columbia.